Targovax ASA announced that it has appointed Dr. Lubor Gaal as Chief Financial Officer (CFO), effective as of 7 March 2022. Most recently, he served as Managing Director and Head of Europe at Locust Walk. Before Locust Walk, he was Head of External Innovation and Licensing and a member of the R&D Management Committee at Almirall and Head of Europe Search and Evaluation for oncology at Bristol-Myers Squibb.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.78 NOK | -2.46% | -20.57% | -61.39% |
05-29 | Transcript : Circio Holding ASA - Special Call | |
05-29 | Norway's Circio Sets Terms of NOK52 Million Rights Issue Proposal | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.39% | 2.23M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- TRVX Stock
- News Circio Holding ASA
- Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022